ReviewDiagnostics (Basel, Switzerland)2022
Diagnosis and Management of Febrile Neutropenia in Pediatric Oncology Patients-A Systematic Review.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06188182 (D-index as a Predictor of Complications of Febrile Neutropenia in Patients With Acute Myeloid Leukemia), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
D-index as a Predictor of Complications of Febrile Neutropenia in Patients With Acute Myeloid Leukemia
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Multidrug-Resistant Gram-Negative Bacteremia among Pediatric Oncology Patients with Neutropenic Fever: Associated Risk Factors and Mortality Outcomes.Infection & chemotherapy · 2026Article
- Clinical Phenotypes and Glycopeptide Escalation Patterns in Pediatric Febrile Neutropenia: Associations with Short-Term Outcomes and Acute Kidney Injury RiskTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Enhanced detection of sepsis pathogens in hospitalized febrile neutropenia patients using blood culture broths with TaqMan array card.Research square · 2026Article
- Review
- Diagnosis and treatment of invasive fungal disease in children with hematological malignancies after chemotherapy: Challenges and strategies (Review).Experimental and therapeutic medicine · 2026Review
- Early clinical determinants of adverse outcomes in paediatric febrile neutropenia: a prospective cohort study.Frontiers in oncology · 2026Article
- Embedding social determinants in mHealth for pediatric oncology: co-designing a patient-centred tool for febrile neutropenia in resource-limited settings.International journal for equity in health · 2025Article
- Risk Factors for Severe Outcomes Among Pediatric Cancer Patients with Respiratory Viral Infection.Microorganisms · 2025Article
- Role of neutrophil elastase in predicting infection among children with chemotherapy-induced febrile neutropenia.Clinical and experimental pediatrics · 2025Article
- Optimizing Care for Neutropenic Fever in Pediatric Patients: An Analysis of Treatment Approaches and Clinical Outcomes.The Permanente journal · 2025Article
- Utilizing Viral Metagenomics to Characterize Pathogenic and Commensal Viruses in Pediatric Patients with Febrile Neutropenia.Viruses · 2025Article
- Infections in Children with Acute Lymphoblastic Leukemia.Medicina (Kaunas, Lithuania) · 2024Article
- Impact of Time-to-Antibiotic Delivery in Pediatric Patients With Cancer Presenting With Febrile Neutropenia.JCO oncology practice · 2024Article
- Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia.Frontiers in cellular and infection microbiology · 2024Article
- Blood plasma metagenomic next-generation sequencing for identifying pathogens of febrile neutropenia in acute leukemia patients.Scientific reports · 2023Article
- The Effects of Vitamin D Supplementation on Respiratory Infections in Children under 6 Years Old: A Systematic Review.Diseases (Basel, Switzerland) · 2023Review
- Post-Infection Oscillometry and Pulmonary Metrics in SARS-CoV-2 Patients: A 40-Day Follow-Up Study.Diseases (Basel, Switzerland) · 2023Article
- The Applicability of a 2-Transcript Signature to Identify Bacterial Infections in Children with Febrile Neutropenia.Children (Basel, Switzerland) · 2023Article
- The Assessment of Antimicrobial Resistance in Gram-Negative and Gram-Positive Infective Endocarditis: A Multicentric Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2023Article
- Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.Current oncology (Toronto, Ont.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases are associated with a high morbidity and mortality rate among pediatric cancer patients undergoing treatment or receiving a transplant. Neutropenia represents a potentially fatal complication of cancer treatment and is associated with a high risk of developing bacterial infections. Although febrile neutropenia (FN) can affect both adults and children, the latter has a higher chance of infections with an unknown origin. Prompt empiric broad-spectrum antibiotic administration is collectively considered the best therapeutic approach. This review aims to analyze the latest works from the literature regarding the therapeutic strategies, schemes, and approaches and the efficacy of these in pediatric febrile neutropenia. Following PRISMA guidelines, an advanced search on PubMed, Scopus, and Cochrane Library, using the keywords "febrile neutropenia", "pediatric", "cancer", and "oncology", was performed. A total of 197 articles were found to be eligible. After screening the abstracts and excluding unfit studies, 16 articles were analyzed. There were eight retrospective studies, five prospective studies, and two clinical trials. Altogether, these studies have described around 5000 episodes of FN. The median age of the participants was 7.6 years, and the underlying condition for most of them was acute leukemia. The infectious agent could only be determined in around one-fifth of cases, from which 90% were of bacterial origin. As such, empirical broad-spectrum antibiotics are used, with the most used treatment scheme comprising third- and fourth-generation cephalosporins and antipseudomonal penicillins. In order to improve the treatment strategies of FN episodes and to successfully de-escalate treatments toward narrower-spectrum antibiotics, hospitals and clinics should increase their efforts in identifying the underlying cause of FN episodes through blood culture urine culture and viral tests, wherever infrastructure enables it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.